(firstQuint)CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML.

 The relapsed/refractory AML patients will receive FC (F,Fludarabine,C,Cyclophosphamide) chemotherapy followed by infusion of allogenic or autologous CD123-Targeted CAR-T cells.

No graft-versus-host disease (GVHD) prevention will be conducted before or after infusion.

 Dose-limiting toxicity,incidence of adverse events and disease response will be detected post-infusion.

.

 CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML@highlight

The purpose of this study is to evaluate the safety and efficiency of CD123-Targeted CAR-T in Treating Patients with relapsed/refractory AML